Preliminary H1 2026 results show €300.1 million in revenue and -€42.7 million adjusted EBITDA, with FY 2026 guidance lowered due to delayed strategic partnerships and milestone revenues. Base CRO and CDMO segments demonstrated strong sales momentum and operational progress.

Original document:

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.